Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Rating Lowered to Hold at DZ Bank

DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) from a buy rating to a hold rating in a research note released on Friday, The Fly reports.

FMS has been the subject of a number of other research reports. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a buy rating to a neutral rating in a research report on Friday. Truist Financial lowered their target price on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a hold rating for the company in a report on Wednesday, June 22nd. StockNews.com cut Fresenius Medical Care AG & Co. KGaA from a strong-buy rating to a buy rating in a report on Friday, July 15th. JPMorgan Chase & Co. increased their target price on Fresenius Medical Care AG & Co. KGaA from €48.70 ($50.21) to €51.00 ($52.58) and gave the stock an underweight rating in a report on Thursday, May 5th. Finally, Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from an underperform rating to a buy rating and increased their target price for the stock from $30.30 to $33.70 in a report on Monday, June 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $49.01.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.9 %

Shares of NYSE:FMS opened at $18.35 on Friday. Fresenius Medical Care AG & Co. KGaA has a one year low of $18.16 and a one year high of $40.85. The company has a 50 day moving average of $25.31 and a 200-day moving average of $29.99. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.26 and a quick ratio of 0.93. The stock has a market cap of $10.75 billion, a price-to-earnings ratio of 11.69, a P/E/G ratio of 0.85 and a beta of 1.03.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.42% and a return on equity of 6.72%. The business had revenue of $5.10 billion for the quarter, compared to analyst estimates of $4.97 billion. On average, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.79 earnings per share for the current year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 6.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 13,583 shares of the company’s stock valued at $440,000 after purchasing an additional 817 shares during the last quarter. FDx Advisors Inc. acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at about $315,000. Atlas Capital Advisors LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 27.1% in the 4th quarter. Atlas Capital Advisors LLC now owns 9,266 shares of the company’s stock valued at $301,000 after purchasing an additional 1,973 shares during the last quarter. UMB Bank N A MO acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at about $192,000. Finally, Cacti Asset Management LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 35.8% in the 1st quarter. Cacti Asset Management LLC now owns 36,000 shares of the company’s stock valued at $1,212,000 after purchasing an additional 9,500 shares during the last quarter. Institutional investors own 4.73% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

The Fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Want More Great Investing Ideas?

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.